NEW YORK (GenomeWeb) — Strata Oncology said today that it will help identify patients for the National Cancer Institute’s Molecular Analysis for Therapy Choice (NCI-MATCH) precision medicine trial.
Launched in 2015, NCI-MATCH is testing the efficacy of cancer treatments that are selected based on the genomic markers driving patients’ tumors, regardless of cancer type. Strata said it will identify patients for potential enrollment in the study’s various treatment arms through a network of 11 healthcare systems that are using the company’s StrataNGS 87-gene assay to link patients with clinical trials of targeted cancer therapies.
“NCI-MATCH is a discovery trial whose very nature — identifying and exploring knowledge gaps in precision oncology, and advancing new hypotheses — means studying small subsets of patients,” NCI-Match Co-chair and University of Pennsylvania researcher Peter O’Dwyer said in a statement. “We are qualifying additional laboratories so we can cast a wider net for patients with the biomarkers of interest.”
Last month, BioReference Laboratories said that its GenPath Oncology Diagnostics division is also participating in NCI-MATCH by helping to match patients to study treatment arms.
In June, NCI-MATCH investigators reported initial results for three of the study’s treatment arms.